Logo image of CLDX

CELLDEX THERAPEUTICS INC (CLDX) Stock Fundamental Analysis

NASDAQ:CLDX - Nasdaq - US15117B2025 - Common Stock - Currency: USD

20.66  -0.05 (-0.24%)

After market: 20.66 0 (0%)

Fundamental Rating

4

CLDX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. While CLDX has a great health rating, there are worries on its profitability. While showing a medium growth rate, CLDX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLDX has reported negative net income.
CLDX had a negative operating cash flow in the past year.
In the past 5 years CLDX always reported negative net income.
CLDX had a negative operating cash flow in each of the past 5 years.
CLDX Yearly Net Income VS EBIT VS OCF VS FCFCLDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CLDX has a better Return On Assets (-19.92%) than 78.80% of its industry peers.
Looking at the Return On Equity, with a value of -21.13%, CLDX belongs to the top of the industry, outperforming 86.04% of the companies in the same industry.
Industry RankSector Rank
ROA -19.92%
ROE -21.13%
ROIC N/A
ROA(3y)-27.38%
ROA(5y)-24.67%
ROE(3y)-29.51%
ROE(5y)-26.78%
ROIC(3y)N/A
ROIC(5y)N/A
CLDX Yearly ROA, ROE, ROICCLDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLDX Yearly Profit, Operating, Gross MarginsCLDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

CLDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLDX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CLDX has more shares outstanding
CLDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLDX Yearly Shares OutstandingCLDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLDX Yearly Total Debt VS Total AssetsCLDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 15.71 indicates that CLDX is not in any danger for bankruptcy at the moment.
CLDX has a better Altman-Z score (15.71) than 92.23% of its industry peers.
There is no outstanding debt for CLDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.71
ROIC/WACCN/A
WACC10.04%
CLDX Yearly LT Debt VS Equity VS FCFCLDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CLDX has a Current Ratio of 18.91. This indicates that CLDX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 18.91, CLDX belongs to the best of the industry, outperforming 94.17% of the companies in the same industry.
A Quick Ratio of 18.91 indicates that CLDX has no problem at all paying its short term obligations.
CLDX has a better Quick ratio (18.91) than 94.17% of its industry peers.
Industry RankSector Rank
Current Ratio 18.91
Quick Ratio 18.91
CLDX Yearly Current Assets VS Current LiabilitesCLDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

CLDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.81%, which is quite good.
The Revenue has been growing slightly by 1.87% in the past year.
CLDX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.48% yearly.
EPS 1Y (TTM)15.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.46%
Revenue 1Y (TTM)1.87%
Revenue growth 3Y14.72%
Revenue growth 5Y14.48%
Sales Q2Q%-71.56%

3.2 Future

The Earnings Per Share is expected to grow by 28.25% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 159.75% on average over the next years. This is a very strong growth
EPS Next Y-36.45%
EPS Next 2Y-27.92%
EPS Next 3Y-16.02%
EPS Next 5Y28.25%
Revenue Next Year-41.63%
Revenue Next 2Y-27.28%
Revenue Next 3Y86.45%
Revenue Next 5Y159.75%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLDX Yearly Revenue VS EstimatesCLDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
CLDX Yearly EPS VS EstimatesCLDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 -10 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLDX Price Earnings VS Forward Price EarningsCLDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLDX Per share dataCLDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

CLDX's earnings are expected to decrease with -16.02% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.92%
EPS Next 3Y-16.02%

More info and screens

0

5. Dividend

5.1 Amount

CLDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLDEX THERAPEUTICS INC

NASDAQ:CLDX (5/2/2025, 8:00:00 PM)

After market: 20.66 0 (0%)

20.66

-0.05 (-0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01
Earnings (Next)08-06 2025-08-06
Inst Owners112.79%
Inst Owner Change-0.09%
Ins Owners0.21%
Ins Owner Change0.1%
Market Cap1.37B
Analysts84
Price Target63.33 (206.53%)
Short Float %13.27%
Short Ratio11.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.96%
Min EPS beat(2)5.21%
Max EPS beat(2)6.71%
EPS beat(4)4
Avg EPS beat(4)10.68%
Min EPS beat(4)5.21%
Max EPS beat(4)20.89%
EPS beat(8)6
Avg EPS beat(8)3.07%
EPS beat(12)8
Avg EPS beat(12)1.28%
EPS beat(16)9
Avg EPS beat(16)0%
Revenue beat(2)2
Avg Revenue beat(2)140.47%
Min Revenue beat(2)3.25%
Max Revenue beat(2)277.69%
Revenue beat(4)3
Avg Revenue beat(4)99.04%
Min Revenue beat(4)-83.3%
Max Revenue beat(4)277.69%
Revenue beat(8)6
Avg Revenue beat(8)127.03%
Revenue beat(12)8
Avg Revenue beat(12)116.23%
Revenue beat(16)9
Avg Revenue beat(16)103.31%
PT rev (1m)-3.68%
PT rev (3m)-7.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.55%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)221.87%
Revenue NY rev (1m)7.74%
Revenue NY rev (3m)0.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 195.36
P/FCF N/A
P/OCF N/A
P/B 1.84
P/tB 1.91
EV/EBITDA N/A
EPS(TTM)-2.45
EYN/A
EPS(NY)-3.34
Fwd EYN/A
FCF(TTM)-2.41
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0.11
BVpS11.25
TBVpS10.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.92%
ROE -21.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.38%
ROA(5y)-24.67%
ROE(3y)-29.51%
ROE(5y)-26.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.4%
Cap/Sales 27.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.91
Quick Ratio 18.91
Altman-Z 15.71
F-Score4
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)61.32%
Cap/Depr(5y)52.82%
Cap/Sales(3y)43.76%
Cap/Sales(5y)35.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.46%
EPS Next Y-36.45%
EPS Next 2Y-27.92%
EPS Next 3Y-16.02%
EPS Next 5Y28.25%
Revenue 1Y (TTM)1.87%
Revenue growth 3Y14.72%
Revenue growth 5Y14.48%
Sales Q2Q%-71.56%
Revenue Next Year-41.63%
Revenue Next 2Y-27.28%
Revenue Next 3Y86.45%
Revenue Next 5Y159.75%
EBIT growth 1Y-37.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.81%
EBIT Next 3Y-14.41%
EBIT Next 5YN/A
FCF growth 1Y-46.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.06%
OCF growth 3YN/A
OCF growth 5YN/A